The importance of mutation burden in cancer lies in its potential to serve as a biomarker for therapy response, especially in the context of immunotherapy. Immunotherapies, such as checkpoint inhibitors, have shown increased efficacy in tumors with a high mutation burden. This is because a greater number of mutations generates more neoantigens, which can be recognized by the immune system, making it easier to target and eliminate cancer cells.
